Asunaprevir is a selective NS3 protease inhibitor with in vitro activity against HCV genotypes 1 and 4.
Methods
In this Phase IIa double-blind study, treatment-naive HCV genotype-1-infected patients in the United States and France were randomly assigned 1:1:1:1 to placebo or asunaprevir 200 mg twice daily, 600 mg twice daily or 600 mg once daily in combination with pegylated interferon (PEG-IFN)-α2a and ribavirin for 48 weeks. The primary efficacy end point was undetectable HCV RNA at weeks 4 and 12 (extended rapid virological response [eRVR]). Other end points included safety and undetectable HCV RNA at 24 weeks post-treatment (24-week sustained virological response [SVR24]).
Results
A total of 47 patients were randomized and treated. eRVR was achieved by 75% (9/12), 75% (9/12) and 92% (11/12) of patients in the asunaprevir 200 mg twice-daily, 600 mg twice-daily and 600 mg once-daily groups, respectively, versus 0% (0/11) in the placebo group. Corresponding SVR24 rates were 83% (10/12), 83% (10/12) and 92% (11/12) in the asunaprevir groups and 46% (5/11) in the placebo group. There was no virological breakthrough in any asunaprevir group. Following the 12-week analysis, the 600 mg doses were reduced to 200 mg twice daily because of a greater frequency of transaminase elevations at the 600 mg dose. The most common grade 3–4 laboratory abnormalities were consistent with those reported for PEG-IFN and ribavirin.
Conclusions
Asunaprevir plus PEG-IFN and ribavirin achieved higher response rates than placebo plus PEG-IFN and ribavirin, with a tolerable adverse event profile at the 200 mg twice-daily dose. This dose is being evaluated in the Phase IIb and Phase III studies.
References
1.
NegroF., AlbertiA.The global health burden of hepatitis C virus infection. Liver Int2011; 31Suppl 2: 1–3.
ChakE., TalalA.H., ShermanK.E., SchiffE.R., SaabS.Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int2011; 31: 1090–1101.
4.
PerzJ.F., ArmstrongG.L., FarringtonL.A., HutinY.J., BellB P.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol2006; 45: 529–538.
5.
GhanyM.G., NelsonD.R., StraderD.B., ThomasD.L., SeeffL.B.An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology2011; 54: 1433–1444.
6.
CornbergM., RazaviH.A., AlbertiA.A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int2011; 31Suppl 2: 30–60.
7.
SievertW., AltraifI., RazaviH.A.A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int2011; 31Suppl 2: 61–80.
8.
McHutchisonJ.G., LawitzE.J., ShiffmanM.L.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med2009; 361: 580–593.
9.
FriedM.W., ShiffmanM.L., ReddyK.R.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002; 347: 975–982.
10.
PoordadF., McConeJ.Jr., BaconB.R.Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med2011; 364: 1195–1206.
11.
JacobsonI.M., McHutchisonJ.G., DusheikoG.Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med2011; 364: 2405–2416.
12.
McPheeF., SheafferA.K., FriborgJ.Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother2012; 56: 5387–5396.
13.
PasquinelliC., McPheeF., EleyT.Single and multiple ascending dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother2012; 56: 1838–1844.
14.
LokA.S., GardinerD.F., LawitzE.Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med2012; 366: 216–224.
15.
LokA.S., GardinerD., HezodeC.Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A Inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV). Hepatology2012; 56Suppl 1: 230A.
16.
SuzukiY., IkedaK., SuzukiF.Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol2013; 58: 655–662.
17.
McPheeF., FriborgJ., LevineS.Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother2012; 56: 3670–3681.
18.
RomanoK.P., AliA., RoyerW.E., SchifferC.A.Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A2010; 107: 20986–20991.
19.
AithalG.P., WatkinsP.B., AndradeR.J.Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther2011; 89: 806–815.
20.
ChayamaK., TakahashiS., ToyotaJ.Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology2012; 55: 742–748.
21.
LawitzE., Rodriguez-TorresM., StoehrA.A Phase 2b study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. Hepatology2011; 54Suppl 1: 1434A–1435A.
22.
HayashiN., NakamuraK., WrightD.H.Safety and efficacy of vaniprevir (MK-7009) in combination with peg-interferon alfa-2a (peg-IFN)/ribavirin (RBV) in genotype 1 treatment experienced HCV-infected Japanese patients. Hepatology2011; 54Suppl 1: 996A–996A.
23.
LokA., GardinerD., HézodeC.Confirmation that quadruple therapy with daclatasvir (NS5A inhibitor), asunaprevir (NS3 inhibitor) and peginterferon/ribavirin results in high rate of SVR4 in HCV genotype 1 null responders. J Hepatol2012; 56Suppl 2: S557.
